Disease / condition
Non-Small Cell Lung Cancer clinical trials
Free access to 511 studies10+ countriesUpdated daily80 recruiting
VerifiedClinicalTrials.gov · WHO ICTRP · regional registries
511
Total trials
10+
Countries
10+
Sponsors
80
Recruiting
By phase
Phase 2174
N/A124
Phase 396
Phase 158
Early Phase 131
By status
Completed236
Recruiting80
Terminated54
Unknown46
Not yet recruit...37
Top countries
United States of America118
China64
Japan36
Canada10
South Korea9
Top sponsors
Hoffmann-La Roche44
AstraZeneca22
Eli Lilly and Comp...20
Bristol-Myers Squi...18
Genentech, Inc.12
Recent trials
Latest clinical trials for Non-Small Cell Lung Cancer
High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
Changhai Hospital · China
NCT06394674Recruiting
- Phase
- Phase 2
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
Ji Yongling
NCT06379087Not yet recr...
- Phase
- Phase 2
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
AstraZeneca · Australia,Austria,Belgium,Brazil,Canada,Germany,Hungary,India,Italy,Japan,Poland,South Korea,Spain,T
NCT06357533Recruiting
- Phase
- Phase 3
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC
Hunan Province Tumor Hospital · China
NCT06348927Not yet recr...
- Phase
- Phase 2
A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cance... · United States of America
NCT06333678Recruiting
- Phase
- Phase 2
Repositioning Immunotherapy in VetArans With Lung Cancer
VA Office of Research and Deve... · United States of America
NCT06275360Recruiting
- Phase
- Phase 2
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie · United States of America
NCT06236438Recruiting
- Phase
- Phase 2/3
Clinical Effectiveness of Combining Mindfulness-Based Stress Reduction With Exercise Interventione
Shanxi Bethune Hospital · China
NCT06224504Completed
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer
Abbisko Therapeutics Co, Ltd · China,United States of America
NCT06225804Recruiting
- Phase
- Phase 1
A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
Jiangsu Hansoh Pharmaceutical ...
NCT06110663Not yet recr...
- Phase
- Phase 3
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
AbbVie
NCT06093503Not yet recr...
- Phase
- Phase 3
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
Icahn School of Medicine at Mo...
NCT06088771Not yet recr...
- Phase
- Phase 1/2
Pharmacogenomics IND EXEMPT SNP Clinical Study - Crizotinib and Single Nucleotide Polymorphisms
Han Xu, M.D., Ph.D., FAPCR, Sp... · United States of America
NCT06062810Not yet recr...
- Phase
- Phase 2/3
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Avistone Biotechnology Co., Lt... · United States of America
NCT06046495Not yet recr...
- Phase
- Phase 1
Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC
Shouyao Holdings (Beijing) Co.... · China
NCT06031558Recruiting
- Phase
- Phase 3
A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeiGene
NCT06029127Not yet recr...
- Phase
- Phase 2
Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC
Shanghai Zhongshan Hospital
NCT05987826Not yet recr...
- Phase
- Phase 2
Expanded Access to ABBV-400
AbbVie
NCT05982873Available
Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC
Cancer Institute and Hospital,... · China
NCT05974007Recruiting
Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 50 %.
Centre Georges Francois Lecler...
NCT05937906Not yet recr...
- Phase
- Phase 1/2
About this profile
Access comprehensive clinical trial information for Non-Small Cell Lung Cancer through Pure Global AI's free database. This collection includes 511 clinical trials across multiple phases including Phase 2, N/A, Phase 3. Currently, 80 trials are actively recruiting participants.
Research for Non-Small Cell Lung Cancer is being conducted in United States of America, China, Japan and 7+ other countries. Leading sponsors include Hoffmann-La Roche and AstraZeneca. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.
Pure Global AI provides free access to 511 clinical trials studying Non-Small Cell Lung Cancer, aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.
The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 10+ countries.
Top research sponsors include Hoffmann-La Roche, AstraZeneca, Eli Lilly and Company, among others.